Loading...
XTAI4133
Market cap51mUSD
Dec 24, Last price  
27.80TWD
1D
-0.54%
1Q
-9.21%
Jan 2017
-22.65%
IPO
-75.18%
Name

Abnova Taiwan Corp

Chart & Performance

D1W1MN
XTAI:4133 chart
P/E
38.54
P/S
4.41
EPS
0.72
Div Yield, %
2.88%
Shrs. gr., 5y
—
Rev. gr., 5y
-2.16%
Revenues
382m
-7.21%
402,834,000475,072,000472,569,000463,774,000463,699,000438,112,000451,367,000439,826,000475,073,000426,023,000414,158,000456,449,000451,487,000411,756,000382,052,000
Net income
44m
-41.64%
99,558,000149,045,000119,865,00076,838,00072,896,00065,643,00044,911,00053,539,00058,966,00046,118,0003,263,00036,526,00028,369,00074,843,00043,678,000
CFO
76m
-42.42%
63,721,000114,400,000134,225,00076,021,000109,778,00094,180,00073,428,00071,936,00067,529,00089,168,00074,513,000105,300,00092,875,000132,369,00076,219,000
Dividend
Jun 06, 20240.72 TWD/sh
Earnings
May 22, 2025

Profile

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.
URL
https://www.abnova.com/
IPO date
May 27, 2008
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
382,052
-7.21%
411,756
-8.80%
451,487
-1.09%
Cost of revenue
337,911
346,632
406,466
Unusual Expense (Income)
NOPBT
44,141
65,124
45,021
NOPBT Margin
11.55%
15.82%
9.97%
Operating Taxes
4,839
20,113
7,925
Tax Rate
10.96%
30.88%
17.60%
NOPAT
39,302
45,011
37,096
Net income
43,678
-41.64%
74,843
163.82%
28,369
-22.33%
Dividends
(48,443)
(27,855)
(36,332)
Dividend yield
2.28%
1.11%
1.38%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,105
7,199
6,992
Long-term debt
10,307
14,571
8,112
Deferred revenue
Other long-term liabilities
438
526
8,007
Net debt
(408,354)
(345,845)
(328,659)
Cash flow
Cash from operating activities
76,219
132,369
92,875
CAPEX
(19,566)
(13,861)
(834)
Cash from investing activities
36,791
(13,371)
960
Cash from financing activities
(55,620)
(61,400)
(43,803)
FCF
96,878
(15,553)
97,350
Balance
Cash
423,515
367,914
307,266
Long term investments
251
(299)
36,497
Excess cash
404,663
347,027
321,189
Stockholders' equity
811,792
817,467
737,229
Invested Capital
889,800
954,321
901,730
ROIC
4.26%
4.85%
3.98%
ROCE
3.40%
4.98%
3.68%
EV
Common stock shares outstanding
60,632
60,664
60,598
Price
35.10
-14.81%
41.20
-5.40%
43.55
-25.17%
Market cap
2,128,183
-14.85%
2,499,357
-5.29%
2,639,043
-25.16%
EV
1,719,829
2,153,512
2,310,384
EBITDA
76,452
99,617
87,070
EV/EBITDA
22.50
21.62
26.53
Interest
142
152
246
Interest/NOPBT
0.32%
0.23%
0.55%